Comparative Pharmacology
Head-to-head clinical analysis: SOVALDI versus TECHNIVIE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SOVALDI versus TECHNIVIE.
SOVALDI vs TECHNIVIE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sofosbuvir is a nucleotide analog inhibitor of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, which is essential for viral replication. It is converted to the active triphosphate form (GS-461203) that competes with natural nucleotides and causes chain termination upon incorporation into viral RNA.
Technivie is a fixed-dose combination of ombitasvir, paritaprevir, and ritonavir. Ombitasvir is an NS5A inhibitor that inhibits HCV RNA replication and virion assembly. Paritaprevir is an NS3/4A serine protease inhibitor that prevents cleavage of the HCV polyprotein. Ritonavir is a pharmacokinetic enhancer that inhibits CYP3A-mediated metabolism of paritaprevir, increasing its plasma levels.
400 mg orally once daily with or without food.
TECHNIVIE (ombitasvir, paritaprevir, and ritonavir) is administered orally as two fixed-dose combination tablets (each containing ombitasvir 12.5 mg, paritaprevir 75 mg, and ritonavir 50 mg) taken once daily in the morning with food, in combination with dasabuvir (250 mg twice daily with food) for genotype 1b or with ribavirin for genotype 1a.
None Documented
None Documented
Terminal half-life of sofosbuvir is approximately 0.4-0.5 hours; the predominant circulating metabolite GS-331007 has a terminal half-life of 27 hours. This long half-life supports once-daily dosing.
Terminal half-life approximately 40 hours, supporting once-daily dosing
Primarily fecal (77% of absorbed dose as metabolites, 3.5% as unchanged drug) with minor renal elimination (3.5% total, mainly metabolites). Biliary excretion contributes to fecal elimination.
Biliary/fecal (majority, >90% as unchanged drug); renal (<1%)
Category C
Category C
Direct-acting antiviral
Direct-acting antiviral